Methodological Issues in Clinical Drug Development for Essential Tremor

Essential tremor (ET) is one of the most common tremor disorders in the world. Despite this, only two medications have received Level A recommendations from the American Academy of Neurology to treat it (primidone and propranolol). Even though these medications provide relief to a large group of ET...

Descripción completa

Detalles Bibliográficos
Autores principales: Carranza, Michael A., Snyder, Madeline R., Elble, Rodger J., Boutzoukas, Angelique E., Zesiewicz, Theresa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia University Libraries/Information Services 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570037/
https://www.ncbi.nlm.nih.gov/pubmed/23440401
_version_ 1782258998687301632
author Carranza, Michael A.
Snyder, Madeline R.
Elble, Rodger J.
Boutzoukas, Angelique E.
Zesiewicz, Theresa A.
author_facet Carranza, Michael A.
Snyder, Madeline R.
Elble, Rodger J.
Boutzoukas, Angelique E.
Zesiewicz, Theresa A.
author_sort Carranza, Michael A.
collection PubMed
description Essential tremor (ET) is one of the most common tremor disorders in the world. Despite this, only two medications have received Level A recommendations from the American Academy of Neurology to treat it (primidone and propranolol). Even though these medications provide relief to a large group of ET patients, up to 50% of patients are non-responders. Additional medications to treat ET are needed. This review discusses some of the methodological issues that should be addressed for quality clinical drug development in ET.
format Online
Article
Text
id pubmed-3570037
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Columbia University Libraries/Information Services
record_format MEDLINE/PubMed
spelling pubmed-35700372013-02-25 Methodological Issues in Clinical Drug Development for Essential Tremor Carranza, Michael A. Snyder, Madeline R. Elble, Rodger J. Boutzoukas, Angelique E. Zesiewicz, Theresa A. Tremor Other Hyperkinet Mov (N Y) Review Essential tremor (ET) is one of the most common tremor disorders in the world. Despite this, only two medications have received Level A recommendations from the American Academy of Neurology to treat it (primidone and propranolol). Even though these medications provide relief to a large group of ET patients, up to 50% of patients are non-responders. Additional medications to treat ET are needed. This review discusses some of the methodological issues that should be addressed for quality clinical drug development in ET. Columbia University Libraries/Information Services 2012-08-06 /pmc/articles/PMC3570037/ /pubmed/23440401 Text en http://creativecommons.org/licenses/by-nc-nd/3.0/us/ This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommerical–No Derivatives License, which permits the user to copy, distribute, and transmit the work provided that the original author and source are credited; that no commercial use is made of the work; and that the work is not altered or transformed.
spellingShingle Review
Carranza, Michael A.
Snyder, Madeline R.
Elble, Rodger J.
Boutzoukas, Angelique E.
Zesiewicz, Theresa A.
Methodological Issues in Clinical Drug Development for Essential Tremor
title Methodological Issues in Clinical Drug Development for Essential Tremor
title_full Methodological Issues in Clinical Drug Development for Essential Tremor
title_fullStr Methodological Issues in Clinical Drug Development for Essential Tremor
title_full_unstemmed Methodological Issues in Clinical Drug Development for Essential Tremor
title_short Methodological Issues in Clinical Drug Development for Essential Tremor
title_sort methodological issues in clinical drug development for essential tremor
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570037/
https://www.ncbi.nlm.nih.gov/pubmed/23440401
work_keys_str_mv AT carranzamichaela methodologicalissuesinclinicaldrugdevelopmentforessentialtremor
AT snydermadeliner methodologicalissuesinclinicaldrugdevelopmentforessentialtremor
AT elblerodgerj methodologicalissuesinclinicaldrugdevelopmentforessentialtremor
AT boutzoukasangeliquee methodologicalissuesinclinicaldrugdevelopmentforessentialtremor
AT zesiewicztheresaa methodologicalissuesinclinicaldrugdevelopmentforessentialtremor

Ejemplares similares